IN SILICO ANALYSIS OF PHYTOCHEMICALS FROM ZINGIBER OFFICINALE FOR THE INHIBITION OF TUMOR PROTEIN-53 BINDING PROTEIN 1 ASSOCIATED WITH HEPATOCELLULAR CARCINOMA
Keywords:Hepatocellular carcinoma, Phytochemicals, Ginger, Molecular docking, Lipinski rule, Ramachandran plot, Visualisation
Objectives: The bioactive phytocompounds present in Zingiber officinale were assessed for their tumor-suppressing activity against TP-53 BP1 linked to hepatocellular carcinoma.
Methods: The study investigates the interaction of the phytochemicals from Ginger (Zingiber officinale) with the tumor protein TP53. Drug likeness of the chosen ligand was evaluated using SWISS ADME. The Autodock tools were used to investigate the interactions of the ligands with that TP-53 BP1 protein. The docking interactions were visualized using PLIP (Protein-Ligand Interaction Profiler).
Results: It is observed that all the ligands show high gastrointestinal absorption along with the presence of blood-brain barrier permeability and have moderate solubility whereas Gingerenone A exhibits high solubility up to par. Docking analysis shows high-efficiency binding of the ligand (Gingerol) to the receptor.
Conclusion: The bioactive ligand gingerol is a beta-hydroxy ketone compound that displays better binding with the tumor proteins.
McGlynn KA, Petrick JL, El‐Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021;73:4-13.
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.
Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol 2020;72:250-61.
Craig AJ, Von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:139-52.
Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156:477-91.e1.
Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Targeted Ther 2020;5:146.
Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol 2018;19 222-32.
Kim E, Viatour P. Hepatocellular carcinoma: Old friends and new tricks. Exp Mol Med 2020;52:1898-907.
Mahomoodally MF, Aumeeruddy MZ, Rengasamy KR, Roshan S, Hammad S, Pandohee J, et al. Ginger and its active compounds in cancer therapy: From folk uses to nano-therapeutic applications. Semin Cancer Biol 2021;69:140-9.
Almatroudi A, Alsahli MA, Alrumaihi F, Allemailem KS, Rahmani AH. Ginger: A novel strategy to battle cancer through modulating cell signalling pathways: A review. Curr Pharm Biotechnol 2019;20:5-16.
Su P, Veeraraghavan VP, Krishna Mohan S, Lu W. A ginger derivative, zingerone-a phenolic compound-induces ROS‐mediated apoptosis in colon cancer cells (HCT‐116). J Biochem Mol Toxicol 2019;33:e22403.
Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. Swiss-model: Homology modelling of protein structures and complexes. Nucleic Acids Res 2018;46:W296-303.
Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res 2021;49:D1388-95.
Bakchi B, Krishna AD, Sreecharan E, Ganesh VB, Niharika M, Maharshi S, et al. An overview on applications of swissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: A medicinal chemist’s perspective. J Mol Struct 2022;1259:132712.
Pawar RP, Rohane SH. Role of autodock vina in PyRx molecular docking. Asian J Res Chem 2021;14:132-4.
Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ, et al. PLIP 2021: Expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res 2021;49:W530-4.
How to Cite
Copyright (c) 2022 SAMEER SHARMA
This work is licensed under a Creative Commons Attribution 4.0 International License.